Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECSA trial of dexamethasone versus primary surgery for symptomatic chronic subdural hematoma
NL-OMON55350Phase 3Recruiting
- Sponsor
- Haaglanden Medical Centre
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in Chronic subdural haematoma (CSDH) (2 arms), sponsored by Haaglanden Medical Centre. Primary endpoints: Functional outcome at 3 months and Cost-effectiveness at 12 months. Started Sep 2016; status: recruiting.
02
Drugs
dexamethasone
03
Conditions
Chronic subdural haematoma (CSDH)
Beyond the preview
Go deeper on NL-OMON55350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55350.